Please join us to discuss the launch of the second-ever Phase 2 study of a rectal microbicide candidate. If successful, this product would be the first behaviorally congruent biomedical HIV prevention intervention. Hear directly from HPTN researchers leading the study during this exciting webinar hosted by The Choice Agenda.
HPTN 106 (REV UP) is an innovative clinical trial from the HIV Prevention Trials Network investigating the safety and acceptability of a tenofovir-based rectal douche for HIV prevention among cisgender men and transgender women who have sex with men.
Speakers:
Dr. Craig Hendrix, Johns Hopkins University School of Medicine
Dr. Mark Marzinke, Johns Hopkins University School of Medicine
Moderator:
Jim Pickett, The Choice Agenda